Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT) Following Positive Briefing Docs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
PBC Committee Opens The Door to $2.2B Opportunity For Intercept Pharma (ICPT) - Wedbush
April 6, 2016 7:50 AM EDTWedbush analyst, Liana Moussatos, reviewed the FDA's briefing documents for Intercept Pharmaceuticals (NASDAQ: ICPT) obeticholic acid (OCA) in primary biliary cholangitis (PBC) Advisory Committee meeting and does not see any major red flags for approval.
As the analyst anticipated, the FDA appears to be focused on the validity of the primary endpoints (ALP... More
Intercept Pharmaceuticals (ICPT) Briefing Docs 'Mostly In-Line' - FBR Capital
April 5, 2016 11:07 AM EDTFBR Capital analyst Vernon Bernardino reiterated a Market Perform rating and $192 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) the FDA released briefing documents ahead of the April 7 meeting of its Gastrointestinal Drugs Advisory Committee (GIDAC) to discuss ICPT's new New Drug Application (NDA) for approval to use obeticholic acid (OCA), which is the company's investigational treatment for primary... More
Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - Leerink
April 5, 2016 9:33 AM EDTLeerink affirms Intercept Pharma (Nasdaq: ICPT) at Market Perform with a price target of $144 as OCA briefing docs were posted ahead of an FDA panel this week.
ANalyst Joseph Schwartz commented, the FDA briefing documents for obeticholic acid (OCA) were released this morning and are largely in line with our recently-outlined expectations (LINK) and we maintain our opinion that ICPT is likely to receive a positive panel vote on Thursday, 4/7, and secure approval in the primary biliary cholangitis (PBC) indication by... More
Wells Fargo Upgrades Intercept Pharmaceuticals (ICPT) to Outperform
April 5, 2016 9:02 AM EDTWells Fargo upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Shares of Intercept Pharmaceuticals closed at $133.55 yesterday.
... MoreIntercept Pharma (ICPT) FDA Briefing Documents Posted
April 5, 2016 8:01 AM EDTIntercept Pharma (NASDAQ: ICPT) FDA briefing documents posted. LINK
... More